By Alex Glenn • Published: 07 Dec 2020 • 16:11
TWO batches of the heart drug Solinitrin 0.8 mg sublingual tablets have been withdrawn to due to quality issues.
The heart drug is in sublingual tablets and is given for myocardial ischemia and after heart attacks. Two batches of the drug have been withdrawn by the Spanish Agency for Medicines and Health Products after it was discovered that they contain a lower than expected nitroglycerin content. The batch numbers are R002 and R003.
There are alternative drugs available and the Solinitrin 0.8 mg sublingual tablets will not be marketed again until the quality issue is fully solved.
The drug is normally taken orally by chewing and then keeping under the tongue in order to aid absorption.
Thank you for taking the time to read this news article “Heart Drug Withdrawn Due to Safety Concerns in Spain”. For more UK daily news, Spanish daily news and Global news stories, visit the Euro Weekly News home page.
Share this story
Subscribe to our Euro Weekly News alerts to get the latest stories into your inbox!
By signing up, you will create a Euro Weekly News account if you don't already have one. Review our Privacy Policy for more information about our privacy practices.
Originally from the UK, Alex is based in Almeria and is a web reporter for The Euro Weekly News covering international and Spanish national news. Got a news story you want to share? Then get in touch at editorial@euroweeklynews.com.
By signing up, you will create a Euro Weekly News account if you don’t already have one. Review our Privacy Policy for more information about our privacy practices.
Download our media pack in either English or Spanish.